<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808002</url>
  </required_header>
  <id_info>
    <org_study_id>MARAVIBOOST</org_study_id>
    <nct_id>NCT00808002</nct_id>
  </id_info>
  <brief_title>Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine</brief_title>
  <official_title>Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intensification with maraviroc in recently HIV-1-infected patients of a preferred
      gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could
      accelerate the decay of the HIV-1 reservoir in latently infected cells established early in
      HIV-1 infection.

      This could provide further insight into this area, decrease the size of latent reservoir, and
      translate into clinical benefits for patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A reservoir of latently infected cells established early in infection may be involved in the
      maintenance of viral persistence despite continuous highly active antiretroviral therapy
      (HAART). This is likely to represent the major barrier to virus eradication in patients on
      successful combination antiretroviral therapy.

      The majority of the viruses in the latent reservoir use CCR5 receptor during entry.

      More recently, clear evidences for decay of this HIV-1 reservoir in patients who initiated
      antiretroviral therapy early in infection have been demonstrated. The treatment of acute
      infection may set the stage for subsequent attempts at eradication. To achieve this, more
      potent antiretroviral therapy and/or more potent antilatency therapies may be needed.

      In contrast to previous antiretroviral drugs, maraviroc does not need to cross the cell
      membrane, nor does not require intracellular processing in order to exert its activity. In
      addition, there is no cross-resistance between entry inhibitors and agents that act on
      intracellular targets.

      Maraviroc has demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses
      tested. Maraviroc could thus fulfil the requirements for an optimal candidate for treatment
      intensification in HIV-1 infected patients with a recent HIV-1 infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change at 48 weeks in the slope of decay of integrated and unintegrated viral DNA in PBMCs.</measure>
    <time_frame>BL, W2, W4, W12, W24, W48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decay of residual HIV-1 replication under maraviroc intensification assessed by an ultrasensitive RT-PCR assay with a lower limit of quantification of 5 copies/mL.</measure>
    <time_frame>BL, W2, W4, W8, W12, W24, W36, W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blips during the study (viral load &gt;50 copies/mL, preceded and followed by determinations &lt;50 copies/mL in previous and posterior controls).</measure>
    <time_frame>From Baseline to W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA below 50 copies/mL at 48 weeks.</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the lymphocyte activation marker HLADR+CD38+ from baseline to week 48.</measure>
    <time_frame>BL, W4, W12, W24, W48, W60, W72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between maraviroc and/or raltegravir plasma concentrations and change in the slope of decay of integrated viral DNA in PBMCs</measure>
    <time_frame>W12, W24, W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 specific CTL responses</measure>
    <time_frame>BL, W24, W48, W60, W72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasmatic inflammation biomarkers</measure>
    <time_frame>BL, W2, W4, W12, W48, W60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA, DNA and viral p24 associated to cells in ileum biopsy and PBMC</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte activation marker HLADR+CD38+ in ileum biopsy and PBMC</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis markers in ileum biopsy and PBMC</measure>
    <time_frame>W48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Raltegravir 400 mg every 12 hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>Maraviroc 300 mg every 12 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir/Emtricitabine</intervention_name>
    <description>Tenofovir/Emtricitabine 300/200 mg every 24 hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infected adults (&gt;=18 years old).

          2. No previous antiretroviral therapy for more than 2 weeks.

          3. HIV-1 infection documented in the past 6 months by a previous negative ELISA test, or
             a documented clinical acute seroconversion in the past 6 months.

          4. CCR5-tropism confirmed at screening.

          5. Voluntary written informed consent.

        Exclusion Criteria:

          1. Pregnancy or fertile women willing to be pregnant.

          2. Active substance abuse or major psychiatric disease.

          3. Presence of NRTI mutations in the screening genotype.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLuita contra la SIDA Foundation-HIV Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Mª Llibre, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LLuita contra la SIDA Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2008</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Germans Trias i Pujol Hospital</investigator_affiliation>
    <investigator_full_name>Dr . BONAVENTURA CLOTET</investigator_full_name>
    <investigator_title>Dr. Bonaventura Clotet</investigator_title>
  </responsible_party>
  <keyword>Maraviroc</keyword>
  <keyword>CCR5 antagonists</keyword>
  <keyword>Primary HIV Infection</keyword>
  <keyword>HIV-1 reservoir</keyword>
  <keyword>eradication</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

